A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETIC OF PF 06863135, A B CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT IN JAPANESE PARTICIPANTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Elranatamab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Registrational
- Acronyms MAGNETISMM-2
- Sponsors Pfizer
- 27 Sep 2024 Status changed from active, no longer recruiting to completed.
- 26 Mar 2024 According to a Pfizer media release, based on results from MagnetisMM-3 and MagnetisMM-2 study the company has obtained manufacturing and marketing approval in Japan for Elrefio subcutaneous injection 44mg, 76mg in Japan for patients with relapsed or refractory multiple myeloma.
- 12 Dec 2023 Results from pooled analysis of MagnetisMM-1 (NCT03269136) study, the Japan Phase 1 MagnetisMM-2 (NCT04798586) study, MagnetisMM-3 (NCT04649359) study, and a Phase 1/2 MagnetisMM-9 (NCT05014412) study evaluating baseline correlation with key disease biomarkers, presented at the 65th American Society of Hematology Annual Meeting and Exposition.